1. Home
  2. MQY vs ANNX Comparison

MQY vs ANNX Comparison

Compare MQY & ANNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Blackrock MuniYield Quality Fund Inc.

MQY

Blackrock MuniYield Quality Fund Inc.

HOLD

Current Price

$11.54

Market Cap

821.8M

Sector

Finance

ML Signal

HOLD

Logo Annexon Inc.

ANNX

Annexon Inc.

HOLD

Current Price

$5.27

Market Cap

812.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MQY
ANNX
Founded
N/A
2011
Country
United States
United States
Employees
N/A
N/A
Industry
Investment Bankers/Brokers/Service
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
821.8M
812.7M
IPO Year
1994
2020

Fundamental Metrics

Financial Performance
Metric
MQY
ANNX
Price
$11.54
$5.27
Analyst Decision
Strong Buy
Analyst Count
0
6
Target Price
N/A
$16.50
AVG Volume (30 Days)
376.9K
3.1M
Earning Date
01-01-0001
05-11-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$16,320.74
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$10.78
$1.85
52 Week High
$11.94
$7.18

Technical Indicators

Market Signals
Indicator
MQY
ANNX
Relative Strength Index (RSI) 58.66 53.20
Support Level $11.46 $5.28
Resistance Level $11.89 $5.79
Average True Range (ATR) 0.09 0.37
MACD 0.01 0.06
Stochastic Oscillator 85.29 73.68

Price Performance

Historical Comparison
MQY
ANNX

About MQY Blackrock MuniYield Quality Fund Inc.

Blackrock Muniyield Quality Fund Inc is a closed-end management investment company. The company's objective is to provide shareholders with as high a level of current income exempt from U.S. federal income taxes as is consistent with its investment policies and prudent investment management. The company invests in Transportation, Corporate, Health, Utilities, Education, Housing, and other sectors.

About ANNX Annexon Inc.

Annexon Inc is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain, and eye. Its pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q. Its pipeline of product candidates is designed to block the activity of C1q and the entire classical complement pathway in a broad set of complement-mediated diseases. Its product candidates are ANX005, for autoimmune & neurodegenerative disorders; ANX007, for neurodegenerative ophthalmic disorders; ANX1502, for Oral small molecule; and ANX009, for systemic autoimmune diseases.

Share on Social Networks: